NCT06578520View on ClinicalTrials.gov

Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure

PHASE4RecruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 31, 2025

Conditions
Heart Failure
Interventions
DRUG

Dapagliflozin

10 mg once per day, oral tablets

Trial Locations (1)

46010

RECRUITING

Hospital Clínico Universitario de Valencia, Valencia

All Listed Sponsors
lead

Fundación para la Investigación del Hospital Clínico de Valencia

OTHER

NCT06578520 - Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure | Biotech Hunter | Biotech Hunter